Bhat Amends Reviva Pharma Stake Filing

TL;DR

CEO Bhat is changing how he reports his Reviva Pharma shares. Watch this space.

AI Summary

Laxminarayan Bhat, CEO of Reviva Pharmaceuticals Holdings, Inc., filed an amendment (SC 13D/A) on August 23, 2024, related to his beneficial ownership of the company's common stock. The filing indicates a change in reporting, with Bhat now filing as an individual rather than through a previous entity. The specific details of the ownership change or the exact number of shares held are not detailed in this excerpt.

Why It Matters

This filing signals a change in how the CEO's stake in Reviva Pharmaceuticals is reported, which could impact transparency for investors regarding control and ownership.

Risk Assessment

Risk Level: medium — Changes in beneficial ownership filings can sometimes precede significant corporate actions or indicate shifts in control, warranting investor attention.

Key Players & Entities

• Laxminarayan Bhat (person) — CEO and filer
• Reviva Pharmaceuticals Holdings, Inc. (company) — Subject company
• Tenzing Acquisition Corp. (company) — Former company name

FAQ

Key Financial Figures

• $0.0001 — ame of Issuer) Common Stock, par value $0.0001 per share (Title of Class of Securitie

Filing Documents

• bhat20240822_sc13da.htm (SC 13D/A) — 31KB
• 0001437749-24-027667.txt ( ) — 33KB

INTEREST IN SECURITIES OF THE ISSUER

ITEM 5. INTEREST IN SECURITIES OF THE ISSUER.

of the Schedule 13D is hereby amended and restated in its entirety as follows

Item 5 of the Schedule 13D is hereby amended and restated in its entirety as follows: (a-b) As of the filing date of this Amendment (the "Filing Date"), for purposes of Rule 13d-3 promulgated under the Act, the Reporting Person is the beneficial owner of an aggregate of 2,893,914 shares of Common Stock, which represents approximately 8.6% of the outstanding shares of Common Stock, based on 33,093,556 shares of Common Stock outstanding as of August 22, 2024, as reported directly by the Issuer to the Reporting Person. Of the 2,893,914 shares of Common Stock reported as beneficially owned by the Reporting Person herein, for purposes of Rule 13d-3 under the Act, the Reporting Person: (A) has sole voting power and dispositive power with respect to an aggregate of 2,780,345 of such shares, consisting of (i) 2,478,856 shares of Common Stock held by the Reporting Person, and (ii) 301,489 shares of Common Stock issuable upon the exercise of options held by the Reporting Person that are exercisable or will be exercisable within 60 days of the Filing Date; and (B) may be deemed to share voting power and dispositive power with respect to an aggregate of 113,569 of such shares, consisting of (i) 5,388 shares of Common Stock held by the Reporting Person's spouse, and (ii) 108,181 shares of Common Stock issuable upon the exercise of options held by the Reporting Person's spouse that are exercisable or will be exercisable within 60 days of the Filing Date. (c) The Reporting Person has not effected any transactions in the Common Stock or securities convertible into, exercisable for or exchangeable for, shares of Common Stock during the period commencing 60 days prior to August 22, 2024 or during the period commencing 60 days prior to the Filing Date. (d) Except as otherwise reported herein, no person or entity other than the Reporting Person has the right to receive, or the power to direct the receipt of dividends from, or the proceeds from the sale of the shares of the Common St